ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, has successfully completed the Performance Evaluation study of the COVID-19 antibody test, initially created by AstraZeneca, with impressive results. The assay …

ProAxsis Limited, the Belfast-based diagnostics company, today announces an expansion of its activities in Asia, via a partnership with Kyberlife, a Singapore-based company offering a novel e-commerce platform. The …

ProAxsis Limited, the Belfast-based diagnostics company, today announces that in partnership with Dr Rich Williams, a Senior Lecturer in the School of Medicine, Dentistry and BioMedical Sciences at Queen’s …

Introduction As 2022 commences, I am pleased to provide an update on the progress made with regard to a number of the company’s key objectives announced during 2021.  The …

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce the appointment of Alison Gillan as its new Management Accountant.  Alison Gillan …

Dr Darragh McCafferty, ProAxsis’ Head of Assay Development, will be presenting new data on the company’s ongoing project to develop a quantitative version of its neutrophil elastase point-of-care test …

Our CEO, Dr David Ribeiro, will be attending the DxPx Conference, taking place face-to-face in Dusseldorf and in a virtual format, November 12th – 20th 2021. ProAxsis are actively …

ProAxsis is delighted to announce the approval of a key US patent for the underlying technology associated with its brand-new K-POSTN Assay, which the company intends to launch shortly. …

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it has been awarded funding for a high impact development project from the Northern Ireland Department for the Economy.  The …